Review of Treatment Options for Lyme Borreliosis

References

• Steere AC, Malawista SE, Hardin JA, Ruddy S, Askenase W, Andiman WA. Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum. Ann Intern Med 1977; 86: 685–698.
   PubMed Web of Science ®Google Scholar
• Sigal LH, Zahradnik JM, Lavin P et al. A vaccine con-sisting of recombinant Borrelia burgdorferi outer-surface pro-tein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med 1998; 339; 216–222.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Lyme Disease. MMWR 2001; 50 (10): 181-185.
   Google Scholar
• Schafer C, Hahn M, Oschmann P. Tick ecology and epi-demiology. In: Oschmann P, Kraiczy P, Halperin J, Brade V, eds. Lyme Borreliosis and Tick-Borne Encephalitis. Bremen, Germany: UNI-MED, 1999: 30–34.
   Google Scholar
• Steere AC. Lyme Disease. N Engl J Med 2001; 345: 115–125.
   PubMed Web of Science ®Google Scholar
• Stanek G, Strle F. Lyme borreliosis. Lancet 2003; 362: 1639–1647.
   PubMed Web of Science ®Google Scholar
• Singh SK, Girschick HJ. Lyme borreliosis: from infection to autoimmunity. Clin Microbiol Infect 2004; 10: 598–614.
   PubMed Web of Science ®Google Scholar
• Franz JK, Krause A. Lyme disease (Lyme borreliosis). Best Pract Res Clin Rheumatol 2003; 17: 241–264.
   PubMed Web of Science ®Google Scholar
• Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med 1994; 330: 229–234.
   PubMed Web of Science ®Google Scholar
• Kalish RA, McHugh G, Granquist J, Shae B, Ruthazer R, Steere AC. Persistence of immunoglobin M or immunoglo-bin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001; 33: 780–785.
   PubMed Web of Science ®Google Scholar
• Dennis DT, Hayes EB, Orloski KA, Meltzer MI. Recommendations for the use of Lyme disease vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999 June 04; 48 (RR07): 1-17.
   Google Scholar
• Shapiro ED, Gerber MA. Lyme disease. Clin Infect Dis 2000; 31: 533–542.
   PubMed Web of Science ®Google Scholar
• Pavia CS. Current and novel therapies for Lyme dis-ease. Expert Opin Investig Drugs 2003; 12: 1003–1016.
   PubMed Web of Science ®Google Scholar
• Strle F. Principles of the diagnosis and antibiotic treat-ment of Lyme borreliosis. Wien Klin Wochenschr 1999; 111: 911–915.
   PubMed Web of Science ®Google Scholar
• Steere AC. Lyme disease. N Engl J Med 1989; 321: 586–596.
   PubMed Web of Science ®Google Scholar
• Oschmann P, Kaiser R. Therapy and prognosis. In: Oschmann P, Kraiczy P, Halperin J, Brade V, eds. Lyme Borreliosis and Tick-Borne Encephalitis. Bremen, Germany: UNI-MED, 1999: 112–119.
   Google Scholar
• Steere AC, Levin RE, Molloy PJ et al. Treatment of Lyme arthritis. Arthritis Rheum 1994; 37: 878–888.
   PubMed Web of Science ®Google Scholar
• Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clinic Invest 2004; 113: 1093–1101.
   PubMed Web of Science ®Google Scholar
• Brade V, Kraiczy P. Pathogenesis and immune defense. In: Oschmann P, Kraiczy P, Halperin J, Brade V, eds. Lyme Borreliosis and Tick-Borne Encephalitis. Bremen, Germany: UNI-MED, 1999: 42–47.
   Google Scholar
• Logigian EL, Kaplan RF, Steere AC. Chronic neurolog-ic manifestations of Lyme disease. N Engl J Med 1990; 323: 1438–1444.
   PubMed Web of Science ®Google Scholar
• Kalish RA, Kaplan RF, Taylor E, Jones-Woodward L, Workman K, Steere AC. Evaluation of study patients with Lyme disease, 10-20 year follow-up. J Infect Dis 2001; 183: 453–460.
   PubMed Web of Science ®Google Scholar
• Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi. Antimicrob Agents Chemother 1995; 39: 1127–1133.
   PubMed Web of Science ®Google Scholar
• Murgia R, Marchetti F, Cinco M. Comparative bacterio-static and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato. Antimicrob Agents Chemother 1999; 43: 3030–3032.
   PubMed Web of Science ®Google Scholar
• Sicklinger M, Wienecke R, Neubert U. In vitro suscepti-bility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stric-to. J Clin Microbiol 2003; 41: 1791–1793.
   PubMed Web of Science ®Google Scholar
• Preac-Mursic V, Wilske B, Schierz G. European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility. Zentralbl Bakteriol Mikrobiol Hyg [A] 1986; 263: 112–118.
   PubMedGoogle Scholar
• Agger WA, Callister SM, Jobe DA. In vitro susceptibili-ties of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob Agents Chemother 1992; 36: 1788–1790.
   PubMed Web of Science ®Google Scholar
• Li M, Masuzawa T, Wang J, Kawabata M, Yanagihara Y. In-vitro and in-vivo antibiotic susceptibilities of Lyme dis-ease Borrelia isolated in China. J Infect Chemother 2000; 6: 65–67.
   Google Scholar
• Mursic VP, Wilske B, Schierz G, Holmburger M, Suss E. In vitro and in vivo susceptibility of Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis 1987; 6: 424–426.
   Web of Science ®Google Scholar
• Dever LL, Jorgensen JH, Barbour AG. Comparative in vitro activities of clarithromycin, azithromycin, and ery-thromycin against Borrelia burgdorferi. Antimicrob Agents Chemother 1993; 37: 1704–1706.
   PubMed Web of Science ®Google Scholar
• Hunfeld KP, Kraiczy P, Wichelhaus TA, Schafer V, Brade V. Colorimetric in vitro susceptibility testing of peni-cillins, cephalosporins, macrolides, streptogramins, tetracy-clines, and aminoglycosides against Borrelia burgdorferi iso-lates. Int J Antimicrob Agents 2000; 15: 11–17.
   PubMed Web of Science ®Google Scholar
• Johnson RC. Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo. Rev Infect Dis 1989; 11 (Suppl 6): S1505–S1510.
   PubMedGoogle Scholar
• Johnson RC, Kodner CB, Jurkovich PJ, Collins JJ. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother 1990; 34: 2133–2136.
   PubMed Web of Science ®Google Scholar
• Hansen K, Hovmark A, Lebech AM et al. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm Venereol 1992; 72: 297–300.
   PubMed Web of Science ®Google Scholar
• Johnson RC, Kodner C, Russell M, Girard D. In-vitro and in-vivo susceptibility of Borrelia burgdorferi to azithromycin. J Antimicrob Chemother 1990; 25 (Suppl A): 33-38.
   Google Scholar
• Cimperman J, Maraspin V, Lotric-Furlan S, Ruzic-Sabljic E, Avsic-Zupanc T, Strle F. Double infection with tick borne encephalitis virus and Borrelia burgdorferi sensu lato. Wien Klin Wochenschr 2002; 114: 620–2.
   PubMed Web of Science ®Google Scholar
• Nadelman RB, Nowakowski J, Fish D et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme dis-ease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345: 79–84.
   Google Scholar
• Wormser GP, Nadelman RB, Dattwyler RJ et al. Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis 2000; 31 (Suppl 1): S1–14.
   PubMed Web of Science ®Google Scholar
• Luft BJ, Dattwyler RJ, Johnson RC et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med 1996; 124: 785–791.
   PubMed Web of Science ®Google Scholar
• Luger SW, Paparone P, Wormser GP et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995; 39: 661–667.
   PubMed Web of Science ®Google Scholar
• Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992; 117: 273–280.
   PubMed Web of Science ®Google Scholar
• Eppes SC, Childs JA. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics 2002; 109: 1173–1177.
   PubMed Web of Science ®Google Scholar
• Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection 2000; 28: 153–156.
   PubMed Web of Science ®Google Scholar
• Wormser GP, Ramanathan R, Nowakowski J et al. Duration of antibiotic therapy for early Lyme disease. A ran-domized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138: 697–704.
   Google Scholar
• Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis - randomised comparison of ceftriaxone and penicillin. Lancet 1988; 1 (8596): 1191–1194.
   PubMed Web of Science ®Google Scholar
• Oksi J, Nikoskelainen J, Viljanen MK. Comparison of oral cefixime and intravenous ceftriaxone followed by oral amoxicillin in disseminated Lyme borreliosis. Eur J Microbiol Infect Dis 1998; 17: 715–719.
   PubMed Web of Science ®Google Scholar
• Dattwyler RJ, Luft BJ, Kunkel MJ et al. Ceftriaxone compared with doxycycline for the treatment of acute dissemi-nated Lyme disease. N Engl J Med 1997; 337: 289–294.
   PubMed Web of Science ®Google Scholar
• Logigian EL, Kaplan RF, Steere AC. Successful treat-ment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis 1999; 180: 377–383.
   PubMed Web of Science ®Google Scholar
• Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neu-roborreliosis. Neurology 1994; 44: 1203–1207.
   PubMed Web of Science ®Google Scholar
• Karkkonen K, Stiernstedt SH, Karlsson M. Follow-up of patients treated with oral doxycycline for Lyme neuroborrelio-sis. Scand J Infect Dis 2001; 33: 259–262.
   PubMedGoogle Scholar
• Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J. Ceftriaxone in the treatment of Lyme neuroborreliosis. Infection 1996; 24: 88–90.
   PubMed Web of Science ®Google Scholar
• Wahlberg P, Granlund H, Nyman D, Panelius J, Seppala I. Treatment of late Lyme borreliosis. J Infect 1994; 29: 255–261.
   PubMed Web of Science ®Google Scholar
• Kaiser R. Clinical courses of acute and chronic neu-roborreliosis following treatment with ceftriaxone. Nervenarzt 2004; 75: 553–557.
   PubMed Web of Science ®Google Scholar
• Bloom BJ, Wyckoff PM, Meissner HC, Steere AC. Neurocognitive abnormalities in children after classic manifes-tations of Lyme disease. Pediatr Infect Dis J 1998; 17: 189–196.
   PubMed Web of Science ®Google Scholar
• Vázquez M, Sparrow SS, Shapiro ED. Long-term neu-ropsychologic and health outcomes of children with facial nerve palsy attributable to Lyme disease. Pediatrics 2003; 112: e93–e97.
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Kuiper H, Kijlstra A, van Dam AP, Rothova A. Long-term effects of ceftriaxone treatment on intraocular Lyme borreliosis. Am J Ophthalmol 1993; 116: 571–575.
   PubMed Web of Science ®Google Scholar
• Nowakowski J, Nadelman RB, Forseter G, McKenna D, Wormser GP. Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. J Am Acad Dermatol 1995; 32 (2 Pt 1): 223-227.
   Google Scholar
• Smilack JD. The tetracyclines. Mayo Clin Proc 1999; 74: 727–729.
   PubMed Web of Science ®Google Scholar
• Hengge UR, Tannapfel A, Tyring SK, Erbel R, Arendt G, Ruzicka T. Lyme borreliosis. Lancet Infect Dis 2003; 3: 489–500.
   PubMed Web of Science ®Google Scholar
• Donta ST. Macrolide therapy of chronic Lyme Disease. Med Sci Monit 2003; 9: P1136–142.
   Google Scholar
• Wormser GP. Lyme disease: insights into the use of antimicrobials for prevention and treatment in the context of experience with other spirochetal infections. Mt Sinai J Med 1995; 62: 188–195.
   PubMed Web of Science ®Google Scholar
• Jaruratanasirikul S, Hortiwakul R, Tantisarasart T, Phuenpathom N, Tussanasunthornwong S. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob Agents Chemother 1996; 40: 825–826.
   PubMed Web of Science ®Google Scholar
• Verdon ME, Sigal LH. Recognition and management of Lyme disease. Am Fam Physician 1997; 56: 427-436, 439–440.
   Google Scholar
• Nowakowski J, McKenna D, Nadelman RB et al. Failure of treatment with cephalexin for Lyme disease. Arch Fam Med 2000; 9: 563–567.
   PubMedGoogle Scholar
• Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl KM. Randomized comparison of ceftriax-one and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991; 163: 311–318.
   PubMed Web of Science ®Google Scholar
• Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: an update of its use in the management of com-munity-acquired and nosocomial infections. Drugs 2002; 62: 1041–1089.
   PubMed Web of Science ®Google Scholar
• Eppes SC. Diagnosis, treatment, and prevention of Lyme disease in children. Paediatr Drugs 2003; 5: 363–372.
   PubMedGoogle Scholar
• Dattwyler RJ, Halperin JJ, Pass H, Luft BJ. Ceftriaxone as effective therapy in refractory Lyme disease. J Infect Dis 1987; 155: 1322–1325.
   PubMed Web of Science ®Google Scholar
• Luft BJ, Volkman DJ, Halperin JJ, Dattwyler RJ. New chemotherapeutic approaches to the treatment of Lyme borre-liosis. Ann N Y Acad Sci 1988; 539: 352–361.
   PubMed Web of Science ®Google Scholar
• Hassler D, Zoller L, Haude M, Hufnagel HD, Heinrich F, Sonntag HG. Cefotaxime versus penicillin in the late stage of Lyme disease - prospective, randomized therapeutic study. Infection 1990; 18: 16–20.
   PubMed Web of Science ®Google Scholar
• Halperin JJ. Neuroborreliosis (Nervous System Lyme Disease). Curr Treat Options Neurol 1999; 1: 139–146.
   PubMedGoogle Scholar
• Levin JM, Nelson JA, Segreti J, Harrison B, Benson CA, Strle F. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob Agents Chemother 1993; 37: 1444–1446.
   PubMed Web of Science ®Google Scholar
• Lakos A, Nagy G. Effect of an antibiotic combination on the propagation of Borrelia burgdorferi, causative agent of Lyme disease. Ow Hetil 1999; 140: 1529–1532.
   PubMedGoogle Scholar
• Pavia CS, Wormser GP, Nowakowski J, Cacciapuoti A. Efficacy of an evernimicin (5CH27899) in vitro and in an ani-mal model of Lyme disease. Antimicrob Agents Chemother 2001; 45: 936–937.
   PubMed Web of Science ®Google Scholar
• Klempner MS, Hu LT, Evans J et al. Two controlled trials of antibiotic treatment in patients with persistent symp-toms and a history of Lyme disease. N Engl J Med 2001; 345: 85–92.
   Google Scholar
• National Institute of Neurological Disorders and Stroke (NINDS). Clinical Study Protocol Number R01N538636. PET and MRI imaging of persistent Lyme encephalopathy. http://www.clinicaltrials.gov/ct/gui/show/NCT00037479?order=2 (accessed 18 August 2004).
   Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). Clinical Study Protocol Number 96-1-0052: A com-prehensive clinical, microbiological and immunological assess-ment of patients with suspected chronic Lyme infection and selected control populations. http://www.clinicaltrials.gov/ct/gui/show/NCT00001539?order=3 (accessed 18 Aug 2004).
   Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). Clinical Study Protocol Number 02-1-0055: Evaluation, treatment and follow-up of patients with Lyme dis- ease. http://www.clinicaltrials.gov/ct/gui/show/NCT00028080?order=1 (accessed 18 August 2004).
   Google Scholar
• Steere AC, Sikand VK, Meurice F et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 1998; 339: 209–215.
   Google Scholar
• Ridoloxan Plus product information. Aloha Medicinals Inc., Hailu, HI, USA. http://alohamedicinals.com/lyme-aid.htm (accessed 18 August 2004).
   Google Scholar
• Eppes SC, Klein JD, Caputo GM, Rose CD. Physician beliefs, attitudes, and approaches toward Lyme disease in an endemic area. Clin Pediatr (Phila) 1994; 33: 130–134.
   Google Scholar
• Sigal LH. The Lyme disease controversy. Social and financial costs of misdiagnosis and mismanagement. Arch Intern Med 1996; 156: 1493–1500.
   Google Scholar
• Reid MC, Schoen RT, Evans J, Rosenberg JC, Horwitz RI. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 1998; 128: 354–362.
   PubMed Web of Science ®Google Scholar
• Maes E, Lecomte P, Ray N. A cost-of-illness study of Lyme disease in the United States. Clin Ther 1998; 20: 993–1008.
   PubMed Web of Science ®Google Scholar
• Adu A, Armour CL. Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, cef-tazidime and cefotaxime. Drugs 1995; 50: 423–439.
   Google Scholar
• Hotchkies L, Grima DT, Hedayati S. The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost. Clin Ther 1996; 18: 716–725.
   PubMed Web of Science ®Google Scholar
• Stanek G, Kahl O. Chemoprophylaxis for Lyme borre-liosis? Zentralbl Bakteriol 1999; 289: 655–665.
   PubMedGoogle Scholar
• Strle F, Nadelman RB, Cimperman J et al. Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia. Ann Intern Med 1999; 130: 32–36.
   Google Scholar